Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON EAP Follow-up Study in BRAF V600E-mutated Metastatic Colorectal Cancer
jRCT1031220225Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by National Cancer Center Hospital East. Primary endpoint: Overall survival. Started Jul 2022; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1031220225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220225.